Cerulean Pharma Inc. (CERU) Appoints General Counsel

CAMBRIDGE, Mass., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today announced the appointment of Alejandra Carvajal as Vice President, General Counsel.

"Alejandra brings deep legal and industry expertise to Cerulean and strengthens the management team as we advance our nanoparticle-drug conjugates in the clinic. Her experience will be highly relevant as we grow Cerulean," said Oliver Fetzer, Ph.D., President and Chief Executive Officer of Cerulean.

Ms. Carvajal joins Cerulean after a decade-long tenure with Millennium: The Takeda Oncology Company, most recently as Associate General Counsel, where she served as a strategic advisor to the research and development, business development, manufacturing and commercial functions. Prior to joining Millennium, Ms. Carvajal was an attorney with the law firms Day, Berry & Howard, and Hill & Barlow. Ms. Carvajal received her B.A. cum laude from Harvard University and her J.D. cum laude from Georgetown University Law Center.

"It is an exciting time to join Cerulean. Its lead candidate CRLX-101 is currently progressing through clinical trials, including in combination therapy, and holds promise for people living with certain aggressive cancers," said Ms. Carvajal. "I look forward to working with Cerulean's dedicated management team to continue to advance our unique technology, as we aspire to deliver improved cancer therapies."

About Cerulean Pharma

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of nanoparticle-drug conjugates, or NDCs, designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our lead product candidate, CRLX101, is in multiple clinical trials with other cancer treatments, all of which aim to unlock the power of combination therapy. For more information, please visit www.ceruleanrx.com.

Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about the clinical development of our product candidates, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2014 and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

CONTACT: Aurora Krause Cerulean Pharma Inc. Corporate Communications 617-551-9627

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.